448 related articles for article (PubMed ID: 34315858)
1. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
2. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
3. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
4. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
6. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
[TBL] [Abstract][Full Text] [Related]
7. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Tefferi A; Pardanani A; Gangat N
Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
9. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
Saha C; Harrison C
Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
[TBL] [Abstract][Full Text] [Related]
10. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
Diaz AE; Mesa RA
Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
Tremblay D; Mascarenhas J
Expert Opin Pharmacother; 2023 Apr; 24(5):577-585. PubMed ID: 36922391
[TBL] [Abstract][Full Text] [Related]
12. Current and future role of fedratinib in the treatment of myelofibrosis.
Ragheb M; Harrison CN; McLornan DP
Future Oncol; 2020 Feb; 16(6):175-186. PubMed ID: 31971457
[TBL] [Abstract][Full Text] [Related]
13. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
14. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
15. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
16. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract][Full Text] [Related]
18. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
England JT; Gupta V
Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
[TBL] [Abstract][Full Text] [Related]
19. Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y; McLornan DP; Harrison CN
Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
[TBL] [Abstract][Full Text] [Related]
20. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]